Sermorelin in Children Under 12: How to Plan the Transition to Adult Care

What Is Sermorelin and Why Is It Used in Young Children?

Sermorelin acetate is a synthetic analog of the first 29 amino acids of endogenous growth-hormone-releasing hormone (GHRH). Unlike recombinant human growth hormone (rhGH), sermorelin stimulates the child's own pituitary to secrete GH rather than supplying exogenous hormone directly. The FDA approved sermorelin (Geref, Serono) specifically for the long-term treatment of idiopathic growth hormone deficiency (GHD) in children, and that approval applies to the pediatric population [1].

How Sermorelin Differs From Direct rhGH

Because sermorelin acts on GHRH receptors in the anterior pituitary, it preserves the normal pulsatile architecture of GH secretion. A study published in the Journal of Clinical Endocrinology and Metabolism found that GHRH-stimulated GH pulses remain physiologically timed, which may reduce the risk of GH excess compared with fixed-dose subcutaneous rhGH [2]. The clinical implication for children under 12 is that sermorelin therapy produces a more graduated IGF-1 rise, which some pediatric endocrinologists prefer when epiphyseal plates are still actively growing.

Typical Dosing in Children Under 12

The standard approved pediatric dose of sermorelin is 0.2 to 0.3 mcg/kg/day administered as a single subcutaneous injection at bedtime, timed to coincide with the natural nocturnal GH surge [1]. Body weight drives dose adjustments every 3 to 6 months. Children under 12 generally weigh 20 to 45 kg, placing most daily doses in the 4 to 13 mcg range. Dose capping becomes relevant as weight approaches 40 kg to avoid supraphysiologic IGF-1.

Why the Under-12 Window Is Clinically Distinct

Children under 12 occupy a narrow developmental corridor. Bone age, pubertal staging, and hypothalamic-pituitary axis maturation all shift rapidly during this period. A decision made at age 8 about sermorelin therapy may need to be re-evaluated entirely by age 11 because the pituitary's sensitivity to GHRH changes as sex steroids rise during puberty.

Pituitary Sensitivity and Sex Steroid Priming

Sex steroids, particularly estradiol, prime somatotroph cells in the anterior pituitary, amplifying GH pulse amplitude. This means a child on a stable sermorelin dose may show a sharp IGF-1 increase at pubertal onset without any change in the prescribed dose. The Endocrine Society's 2019 Clinical Practice Guideline on Growth Hormone Deficiency in Adults explicitly states: "Patients with childhood-onset GHD should be retested for GHD after completion of linear growth, as GH secretory capacity may normalize with the sex steroid milieu of puberty" [3]. Retesting before that pubertal surge is complete can produce a false-negative result.

Bone Age as a Transition Trigger

Chronological age alone is an unreliable transition marker. Bone age, assessed by a left-hand-and-wrist X-ray using the Greulich and Pyle atlas, gives a more accurate picture of skeletal maturity. Most pediatric endocrinologists schedule the formal transition re-evaluation when bone age reaches 12 to 13 years in girls and 13 to 14 years in boys, regardless of the child's actual birthdate [4]. A child who is chronologically 10 but has a bone age of 12 may need transition planning to begin immediately.

The Evidence Base for Pediatric-to-Adult GHD Transition

The proportion of children diagnosed with GHD who retain the deficiency into adulthood is not trivial. Data from a 2012 longitudinal cohort study (N=208) published in the Journal of Clinical Endocrinology and Metabolism found that only about 25% of children with isolated idiopathic GHD had confirmed adult GHD on retesting, whereas nearly 75% of those with structural hypothalamic-pituitary disease retained deficiency [5]. This discrepancy matters enormously for transition planning: the etiology of the child's GHD is a stronger predictor of adult GHD than the severity of childhood deficiency.

What the Transition Guidelines Say

The Endocrine Society 2019 guideline recommends stopping GH therapy at the completion of linear growth, allowing a washout period of 1 to 3 months, and then performing a formal GH stimulation test using either insulin tolerance testing (ITT) or a glucagon stimulation test (GST) to confirm or exclude adult GHD [3]. The guideline further specifies that a peak GH cutoff of <3 mcg/L on ITT or <3 mcg/L on GST supports the diagnosis of adult GHD when a single additional pituitary hormone deficiency is present, and <5 mcg/L in isolated deficiency with a strong clinical picture [3].

For a child who was on sermorelin rather than rhGH, the washout approach is identical in principle. Sermorelin's half-life is approximately 10 to 12 minutes, and endogenous GH secretion normalizes within days of stopping the drug [1]. A 4-week washout before retesting is generally sufficient.

Growth Velocity as an Interim Marker

Before retesting at transition, serial growth velocity measurements provide a real-time read on therapy adequacy. A growth velocity below 4 cm per year in a child who has not yet reached near-final height is a signal that either the diagnosis should be reconsidered or dosing is subtherapeutic. The Growth Hormone Research Society Workshop on Adult GHD notes that height velocity during childhood GH therapy should exceed 2 standard deviations above the pretreatment baseline velocity in the first year to confirm a clinical response [6].

Building the Transition Protocol: A Step-by-Step Framework

A structured transition from pediatric sermorelin therapy to adult-focused care requires coordination across at least three domains: pharmacologic, diagnostic, and administrative. The steps below reflect synthesis of the Endocrine Society 2019 guidelines, the Growth Hormone Research Society consensus statements, and standard pediatric endocrinology handoff practice.

Step 1: Identify Transition-Eligible Patients Early

Transition planning should begin no later than 12 months before the anticipated date of final height. For most girls this means starting conversations at age 9 to 10; for boys, age 10 to 11. At this stage, the clinical team should document the original etiology of GHD, all prior pituitary imaging findings, and whether any additional pituitary hormone deficiencies exist. Children with organic or structural GHD (for example, craniopharyngioma, septo-optic dysplasia, or prior cranial irradiation) almost certainly need continued adult GH therapy and may not require formal retesting before transitioning [3].

Step 2: Complete a Pituitary MRI Before Stopping Sermorelin

An updated MRI of the hypothalamus and pituitary should be obtained within 6 months of the planned sermorelin discontinuation. Structural changes, including a small or ectopic posterior pituitary, confirm organic disease and may allow the clinician to skip stimulation retesting. A normal MRI in a child with isolated idiopathic GHD is the scenario in which retesting is most informative, because spontaneous normalization of GH secretion is most common in this group [5].

Step 3: Washout and Stimulation Testing

After sermorelin is stopped, a 4-week washout precedes formal stimulation testing. The Endocrine Society recommends ITT as the gold standard, with GST as the preferred alternative when ITT is contraindicated (for example, in patients with a seizure history or cardiovascular disease) [3]. Macimorelin, an oral GHRH mimetic, received FDA approval in 2017 for adult GH deficiency testing and is increasingly used in transition-age patients because of its favorable safety profile [7]. A peak GH below the applicable cutoff confirms adult GHD and justifies initiating adult GH therapy, typically with rhGH at a starting dose of 0.2 to 0.4 mg/day rather than continuing sermorelin, since adult GHD management is almost universally conducted with rhGH [3].

Step 4: Administrative and Care-Team Handoff

The American Academy of Pediatrics policy statement on health care transition recommends that the transfer of care include a written medical summary, a current medication list with doses, a copy of all relevant imaging, laboratory trends over at least 24 months, and direct contact between the outgoing pediatric endocrinologist and the receiving adult endocrinologist [8]. Sermorelin prescriptions written in the pediatric context may not be accepted by adult endocrinology practices, which typically prefer rhGH formulations with established adult dosing literature. Anticipating this formulary shift reduces the risk of a gap in therapy during handoff.

Monitoring Parameters During the Transition Period

Monitoring intensity should actually increase, not decrease, in the 12 months surrounding the transition. The following laboratory and clinical parameters guide clinical decisions during this window.

IGF-1 and IGFBP-3

Insulin-like growth factor 1 (IGF-1) remains the most accessible surrogate marker of GH action. Target IGF-1 during pediatric sermorelin therapy is generally 0 to +2 standard deviations (SDS) for age and sex. At transition, IGF-1 should be measured after the washout period and before stimulation testing. An IGF-1 that falls below -2 SDS off therapy corroborates GHD; a level in the normal range does not exclude it, because IGF-1 can be falsely normal in isolated somatotroph dysfunction [9].

IGFBP-3, which carries and stabilizes IGF-1 in the circulation, provides complementary data. A study published in JCEM (N=107 transition-age patients) found that an IGFBP-3 below -2 SDS in conjunction with a subnormal GH stimulation peak had a sensitivity of 78% and specificity of 84% for confirmed adult GHD [10].

Bone Density Assessment

Children with GHD have lower bone mineral density (BMD) compared with age-matched peers. A 2016 meta-analysis in Osteoporosis International (pooled N=643) found that lumbar spine BMD Z-scores were on average 0.6 SD lower in GHD children than in healthy controls, and that GH therapy partially corrected this deficit [11]. A DXA scan at the time of transition establishes a baseline for adult follow-up. If lumbar spine BMD is below -2 SDS at transition, adult GH therapy is particularly well justified even when biochemical results are borderline.

Fasting Glucose and Insulin Sensitivity

Sermorelin, like direct GH, shifts glucose metabolism toward insulin resistance at supraphysiologic doses. Fasting glucose and HbA1c should be measured at least annually during pediatric therapy. At transition, a complete metabolic panel establishes whether any glucose dysregulation has occurred and whether insulin sensitivity will factor into adult dosing decisions. The FDA prescribing information for sermorelin lists glucose intolerance as an adverse effect requiring monitoring [1].

Special Populations Within the Under-12 Group

Not every child under 12 on sermorelin has the same underlying diagnosis. Three subgroups require distinct transition planning.

Children With Multiple Pituitary Hormone Deficiencies

A child with GHD plus central hypothyroidism, adrenal insufficiency, or diabetes insipidus has organic pituitary disease by definition. The 2019 Endocrine Society guideline notes that multiple pituitary hormone deficiencies predict a 95% to 100% rate of confirmed adult GHD on retesting, and these patients may proceed directly to adult GH therapy without formal stimulation testing at transition [3]. The clinical priority in this group is ensuring all hormone replacements are transferred accurately to the adult care team.

Children Who Had Cranial Irradiation

Radiation to the hypothalamus or pituitary gland causes progressive GH axis dysfunction over years. Children treated for medulloblastoma, ependymoma, or other posterior fossa tumors who receive craniospinal irradiation show GH deficiency rates exceeding 80% by 5 years post-treatment [12]. These patients were likely placed on sermorelin or rhGH well before age 12, and transition to adult oncology or neuroendocrine clinics requires oncology team involvement. A joint tumor board and endocrinology transition conference is appropriate for this group.

Children With Idiopathic Isolated GHD and No Structural Abnormality

This is the group where transition decision-making is most nuanced. Up to 75% of these children will test normal for adult GH secretion after puberty [5]. The appropriate default is to stop sermorelin, complete a washout, retest, and make the decision based on stimulation results rather than presuming ongoing deficiency. Families need to understand that stopping therapy is a diagnostic step, not abandonment of care.

Communicating the Transition Plan to Families

Parents of children under 12 often experience the transition conversation as a threat to remove a therapy that has been working. The pediatric endocrinologist's task is to explain clearly that the goal is to determine whether ongoing GH support is warranted as an adult, not to eliminate support if it truly is needed.

The Growth Hormone Research Society consensus statement recommends that transition be discussed as a process beginning at diagnosis, not as a single conversation at age 12 [6]. Integrating this language into routine visits, starting around the child's eighth birthday, normalizes the eventual retesting and handoff.

Written transition summaries for families should include: the name and contact of the receiving adult endocrinologist, a clear statement of what the retesting involves, expected timelines for results, and what happens in each possible outcome scenario. A child whose retest confirms adult GHD will receive rhGH in adult doses. A child who tests normal will be discharged from GH therapy but should have IGF-1 re-checked at age 25 if symptoms of adult GHD arise [3].

Safety Considerations Specific to Pediatric Sermorelin Use

Sermorelin has a well-characterized safety profile in children, but certain signals deserve attention during the transition window when physiology is changing rapidly.

Antibody formation against sermorelin was documented in early clinical trials. The FDA label notes that a small percentage of children develop antibodies to sermorelin that do not appear to affect clinical response in most cases, but IGF-1 monitoring is the mechanism for detecting any loss of efficacy [1]. If IGF-1 drops unexpectedly in a child who was previously well-controlled, antibody testing and a possible switch to rhGH should be considered before the transition retest.

Injection site reactions, headache, and flushing are the most commonly reported adverse effects in pediatric clinical trials and generally resolve within the first 3 months of therapy [1]. These are less relevant at the transition stage but should be documented in the transfer summary so the adult team is aware of prior tolerability.